Key Insights

Highlights

Success Rate

77% trial completion

Published Results

49 trials with published results (17%)

Research Maturity

137 completed trials (48% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

14.3%

41 terminated out of 286 trials

Success Rate

77.0%

-9.6% vs benchmark

Late-Stage Pipeline

10%

29 trials in Phase 3/4

Results Transparency

36%

49 of 137 completed with results

Key Signals

49 with results77% success41 terminated

Data Visualizations

Phase Distribution

236Total
Not Applicable (83)
Early P 1 (3)
P 1 (46)
P 2 (75)
P 3 (21)
P 4 (8)

Trial Status

Completed137
Unknown42
Terminated41
Recruiting32
Withdrawn16
Active Not Recruiting12

Trial Success Rate

77.0%

Benchmark: 86.6%

Based on 137 completed trials

Clinical Trials (286)

Showing 20 of 20 trials
NCT06237881Phase 1Active Not Recruiting

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

NCT03429036Recruiting

Biospecimen Procurement for Head and Neck Disorders

NCT07741435Recruiting

Methylation Profile Test (Methylscape) in Body Fluids for Multi-Cancer Detection and Monitoring in Colombia

NCT03765918Phase 3Active Not RecruitingPrimary

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

NCT07339176Phase 1Recruiting

Intratumoral N17350 in Advanced Solid Tumors

NCT07711626Not ApplicableRecruitingPrimary

Foot Reflexology and Ta-VNS for Symptom Management in Head and Neck Cancer During CCRT

NCT06003231Phase 2Active Not Recruiting

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

NCT03691714Phase 2Completed

Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT07216833Phase 1Withdrawn

Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT05647122Phase 1Active Not Recruiting

First in Human Study of AZD9592 in Solid Tumors

NCT05811936Not ApplicableRecruiting

The SNAP Tool for Head and Neck Cancer Survivor-Caregiver Dyads

NCT07631871Phase 2Not Yet Recruiting

An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy

NCT07631884Phase 2Not Yet Recruiting

Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor

NCT06458517Not ApplicableNot Yet RecruitingPrimary

Evaluation of Two Methods of Administration of Photobiomodulation in the Context of the Prevention and Treatment of Mucositis Induced by Radiotherapy, During the Treatment of Head and Neck Cancers

NCT07556367Not ApplicableActive Not Recruiting

Post-Radiation Oral Health in Underserved Head and Neck Cancer Patients

NCT02568267Phase 2Active Not Recruiting

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

NCT05218824CompletedPrimary

Collection of Head Images During Radiotherapy

NCT01235052Not ApplicableCompleted

Prognostic Evaluation of 18fmiso Pet-ct in Head and Neck Cancer

NCT05420948Phase 2Recruiting

A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer

NCT05187091Phase 3RecruitingPrimary

The SWOAR Trial Sparing of Swallowing and Aspiration Related Organs at Risk & Submandibular Gland With Intensity Modulated Radiotherapy Versus Standard IMRT in Head and Neck Squamous Cell Carcinomas

Scroll to load more

Research Network

Activity Timeline